Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Stocks in this Quantisnow insightHealth Care
Historical context for SCNI
Across the 5 sessions after earlier SCNI headlines, the stock closed higher 3 times and lower 2 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SCNI | SPY |
|---|---|---|---|
| Mar 2, 2026 | Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept | -4.3% | +0.1% |
| Feb 25, 2026 | Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform | +5.9% | +0.8% |
| Feb 17, 2026 | Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm | +2.9% | +0.2% |
| Jan 7, 2026 | Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL | -3.2% | -0.3% |
| Dec 2, 2025 | Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances | +3.0% | +0.2% |
Quantisnow market dataNASDAQ
SCNI
Scinai Immunotherapeutics Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2015
Get push alerts for SCNI
Full SCNI profile on Quantisnow Follow SCNI and get a push notification the moment its next story breaks.